Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.

doi:10.1200/PO.22.00165

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.

JCO precision oncology - 1 Jul 2022

Bedard Philippe L, Li Shuli, Wisinski Kari B, Yang Eddy S, Limaye Sewanti A, Mitchell Edith P, Zwiebel James A, Moscow Jeffrey A, Gray Robert J, Wang Victoria, McShane Lisa M, Rubinstein Larry V, Patton David R, Williams P Mickey, Hamilton Stanley R, Conley Barbara A, Arteaga Carlos L, Harris Lyndsay N, O'Dwyer Peter J, Chen Alice P, Flaherty Keith T

Abstract excerpt

PURPOSE: National Cancer Institute-Molecular Analysis for Therapy Choice is a multicohort trial that assigns patients with advanced cancers to targeted therapies on the basis of central tumor genomic testing. Arm B evaluated afatinib, an ErbB family tyrosine kinase inhibitor, in patients with ERBB2-activating mutations. METHODS: Eligible patients had selected ERBB2 single-nucleotide variants or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diarrhea

Share to In Situ Hybridization, Fluorescence

Share to Quinazolines

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Share to Stroke Volume

Share to Ventricular Function, Left

Source

Open in PubMed Open full text

Identifiers

PMID: 35939768
DOI: 10.1200/PO.22.00165
PMCID: PMC9384949

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.PMID 35939768Read ↗

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.Semantic proximity Read ↗

Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A.Semantic proximity Read ↗

Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study.Semantic proximity Read ↗

Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial.Semantic proximity Read ↗

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.Semantic proximity Read ↗

Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study.Semantic proximity Read ↗

Second-line Afatinib or Chemotherapy Following Immunochemotherapy for the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: Real-world Effectiveness and Safety From a Multisite Retrospective Chart Review in the USA.Semantic proximity Read ↗

Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1).Semantic proximity Read ↗

Randomized phase II study of preoperative Afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of efficacySemantic proximity Read ↗

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.Semantic proximity Read ↗

Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions.Semantic proximity Read ↗

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.